These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 20716023

  • 1. 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey.
    Ivachtchenko AV, Ivanenkov YA, Tkachenko SE.
    Expert Opin Ther Pat; 2010 Sep; 20(9):1171-96. PubMed ID: 20716023
    [Abstract] [Full Text] [Related]

  • 2. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds.
    Ivachtchenko AV, Ivanenkov YA, Skorenko AV.
    Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857
    [Abstract] [Full Text] [Related]

  • 3. 5-HT2C receptor modulators: a patent survey.
    Lee J, Jung ME, Lee J.
    Expert Opin Ther Pat; 2010 Nov; 20(11):1429-55. PubMed ID: 20849206
    [Abstract] [Full Text] [Related]

  • 4. 5-HT(7) receptor modulators: a medicinal chemistry survey of recent patent literature (2004 - 2009).
    Leopoldo M, Lacivita E, Berardi F, Perrone R.
    Expert Opin Ther Pat; 2010 Jun; 20(6):739-54. PubMed ID: 20476847
    [Abstract] [Full Text] [Related]

  • 5. Recent advances in histamine H3 receptor antagonists/inverse agonists.
    Łazewska D, Kieć-Kononowicz K.
    Expert Opin Ther Pat; 2010 Sep; 20(9):1147-69. PubMed ID: 20716022
    [Abstract] [Full Text] [Related]

  • 6. Current status of inverse agonism at serotonin2A (5-HT2A) and 5-HT2C receptors.
    Aloyo VJ, Berg KA, Spampinato U, Clarke WP, Harvey JA.
    Pharmacol Ther; 2009 Feb; 121(2):160-73. PubMed ID: 19109993
    [Abstract] [Full Text] [Related]

  • 7. Inverse agonism at serotonin and cannabinoid receptors.
    Aloyo VJ, Berg KA, Clarke WP, Spampinato U, Harvey JA.
    Prog Mol Biol Transl Sci; 2010 Feb; 91():1-40. PubMed ID: 20691957
    [Abstract] [Full Text] [Related]

  • 8. P2X purinergic receptor ligands: recently patented compounds.
    Gunosewoyo H, Kassiou M.
    Expert Opin Ther Pat; 2010 May; 20(5):625-46. PubMed ID: 20205618
    [Abstract] [Full Text] [Related]

  • 9. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives.
    Ivachtchenko AV, Ivanenkov YA.
    Expert Opin Ther Pat; 2012 Aug; 22(8):917-64. PubMed ID: 22816965
    [Abstract] [Full Text] [Related]

  • 10. Medicinal chemistry strategies to 5-HT(6) receptor ligands as potential cognitive enhancers and antiobesity agents.
    Holenz J, Pauwels PJ, Díaz JL, Mercè R, Codony X, Buschmann H.
    Drug Discov Today; 2006 Apr; 11(7-8):283-99. PubMed ID: 16580970
    [Abstract] [Full Text] [Related]

  • 11. Recent developments in the inhibitors of neuroinflammation and neurodegeneration: inflammatory oxidative enzymes as a drug target.
    Choi DK, Koppula S, Choi M, Suk K.
    Expert Opin Ther Pat; 2010 Nov; 20(11):1531-46. PubMed ID: 20939683
    [Abstract] [Full Text] [Related]

  • 12. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B.
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract] [Full Text] [Related]

  • 13. Novel GABA(B) receptor positive modulators: a patent survey.
    Froestl W.
    Expert Opin Ther Pat; 2010 Aug; 20(8):1007-17. PubMed ID: 20645682
    [Abstract] [Full Text] [Related]

  • 14. Sigma receptor modulators: a patent review.
    Collina S, Gaggeri R, Marra A, Bassi A, Negrinotti S, Negri F, Rossi D.
    Expert Opin Ther Pat; 2013 May; 23(5):597-613. PubMed ID: 23387851
    [Abstract] [Full Text] [Related]

  • 15. Novel actions of inverse agonists on 5-HT2C receptor systems.
    Berg KA, Stout BD, Cropper JD, Maayani S, Clarke WP.
    Mol Pharmacol; 1999 May; 55(5):863-72. PubMed ID: 10220565
    [Abstract] [Full Text] [Related]

  • 16. Ghrelin receptor modulators: a patent review (2011 - 2014).
    Costantino L, Barlocco D.
    Expert Opin Ther Pat; 2014 Sep; 24(9):1007-19. PubMed ID: 25047815
    [Abstract] [Full Text] [Related]

  • 17. The histamine H3 receptor as a therapeutic drug target for CNS disorders.
    Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D.
    Drug Discov Today; 2009 May; 14(9-10):509-15. PubMed ID: 19429511
    [Abstract] [Full Text] [Related]

  • 18. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).
    Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PP.
    Pharmacol Rev; 1994 Jun; 46(2):157-203. PubMed ID: 7938165
    [Abstract] [Full Text] [Related]

  • 19. Latest advances in cannabinoid receptor agonists.
    Thakur GA, Tichkule R, Bajaj S, Makriyannis A.
    Expert Opin Ther Pat; 2009 Dec; 19(12):1647-73. PubMed ID: 19939187
    [Abstract] [Full Text] [Related]

  • 20. Thrombin receptors and their antagonists: an update on the patent literature.
    Cirino G, Severino B.
    Expert Opin Ther Pat; 2010 Jul; 20(7):875-84. PubMed ID: 20450349
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.